Iridium(iii) complexes as mitochondrial topoisomerase inhibitors against cisplatin-resistant cancer cells†
Abstract
Herein, we developed the first metal-based mitochondrial topoisomerase inhibitors to achieve an effective therapeutic outcome for the therapy of cisplatin-resistant tumour cells.